Please select an option below to help us tailor your newsletter to best suit your content interests!
A phase 1b, multi-center, open-lable study of novel combinations of CC-122, CC-223, CC-292 and rituximab in diffuse large B-cell lymphoma
A phase 1b, multi-center, open-lable study of novel combinations of CC-122, CC-223, CC-292 and rituximab in diffuse large B-cell lymphoma
Biopsy proven DLBCL
Relapsed or refractory to standard treatment
ECOG PS 0-1
Measurable disease
ANC>1.5, plts>50
No CNS involvement
No impared cardiac function
No active tx for diabetes (if on CC-223 arm only)
No prior allo HCT
No auto HCT within 3 months
No systemic anti-cancer tx within 4 weeks_
Primary- safety (DLT); Secondary- ORR, PK